ALIPAY+
Alipay+, a cross-border mobile payment digital platform under Ant International, today announced a year-end campaign to promote sustainable cross-border travel with a series of incentives offered by global partners to users of five leading e-wallets in Asia, including Alipay (the Chinese mainland), AlipayHK (Hong Kong SAR, China), Touch ’n Go eWallet by TNG Digital (Malaysia), GCash (the Philippines), and TrueMoney (Thailand).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231214144228/en/
Alipay+ announced a year-end campaign to promote sustainable cross-border travel with a series of incentives offered by global partners to users of five leading e-wallets in Asia including Alipay, AlipayHK, Touch ’n Go eWallet by TNG Digital, GCash and TrueMoney. (Photo: Business Wire)
The campaign, which will last till December 31, will first be launched for the destinations of Hong Kong SAR, Macao SAR, Japan, South Korea, Singapore, Malaysia and Thailand. Travelers will enjoy a wide array of special offers curated in collaboration with global industry leaders, including ComfortDelGro Taxi, Daimaru Matsuzakaya, Galaxy Macau, King Power, and Lotte Duty Free, as well as local small and micro-sized enterprises (SMEs), including Durian BB in Malaysia and IJOOZ in Singapore, creating a diverse and inclusive selection for travelers.
Supporting Responsible Travel
Ant International is committed to promoting sustainable and responsible tourism across its Alipay+ markets, with an ESG program closely aligned with the UN Sustainable Development Goals (SDGs).
The campaign features special offers from Alipay+ and partners to encourage sustainable travel behavior, such as free overseas mobile data packages, in-app discounts across Alipay+’s extensive merchant network, and opportunities to win 100% rebates at partner stores. Travelers are also rewarded for using more digital payments instead of cash, choosing public transportations over cars, travelling with own toothbrushes instead of using disposable ones, as well as visiting more diverse local destinations to support communities’ economies and preserving local cultures.
Dr Cherry Huang, General Manager of Alipay+ Offline Merchant Services, Ant International said, “Our year-end campaign is not just about travel; it’s about making a positive impact. By collaborating with partners who share our commitment to sustainability, we are offering travelers the chance to explore the world responsibly.”
Digital payment increases international tourism revenue to local SMEs. In 2023, while Alipay expanded cooperation with major international card organizations to facilitate foreign cardholders visiting China, Alipay+ brought 10 Asian e-wallets and banking apps into the Chinese mainland to serve their travelling users, a landmark in international expansion of these leading payment methods. As a result, in 2023, over three million merchants in China, including mom-and-pop shops, closed their first international transactions on Alipay+.
With travel booming between the southern part of the Chinese mainland, Hong Kong SAR and Macao SAR, a total of 220 leading merchants in Shenzhen, south China’s Guangdong province also joined the year-end promotion campaign to attract AlipayHK and mPay users with discount packages worth as much as HK$14,000 (about 1,793 US dollar).
To monitor the ESG impact of the campaign, Alipay+ will collaborate with the Chinese University of Hong Kong (CUHK), and an advisory group consisting of experts from Tsinghua University, Hong Kong University, University of Geneva University and the Northwestern University to measure travelers’ carbon footprint reduction, the impact on local businesses, culture and communities, as well as the impact on business best practices in the ecosystem.
Bruce Zhang, CEO of IJOOZ, a juice vending machine provider in Singapore said, “Every year, IJOOZ generates huge amounts of orange pulps and peels. We recycle orange waste, turning them into valuable resources for making new products. We are happy to join hands with Alipay+ to promote sustainable travel among global tourists visiting Singapore.”
Alipay+ in 2023: A Year of Expanded Growth and Partnerships
Since its launch in 2020, Alipay+, a suite of cross-border payment and marketing solutions, has expanded to connect over 88 million merchants in 57 markets to 1.5 billion payment accounts of over 25 digital wallets, banking apps and Buy Now Pay Later (BNPL) apps.
In the second half of 2023, Alipay+ recorded an estimated 30% increase in total payment volume (TPV) compared to the first six months, and over 70% increase in daily average transactions (DAT). Excluding Alipay, the TPV and DAT of cross-border payments of the rest of Alipay+ partner wallets increased by some 280% and 230% respectively in the second half of 2023.
In terms of transaction volume in 2023, AlipayHK, Kakao Pay, Touch ’n Go eWallet and GCash are among the top 4 most popular Alipay+ partner wallets used by cross-border travelers, aside from Alipay itself. Touch ’n Go eWallet, mPay and TrueMoney are ranked top 3 based on month-on-month (MoM) increase of transaction volume in November 2023. As a result, merchants in the Chinese mainland, Macao SAR, Japan, South Korea and Singapore benefited the most from the surge in cross-border mobile payment.
Alan Ni, CEO of TNG Digital, operator of Touch ’n Go eWallet, said: “Tourism is an important contributor to the local economy, and TNG Digital is committed to making a positive difference with our product and services, especially to encourage sustainable travel. Touch ’n Go eWallet cross-border payments in the Chinese mainland have grown by more than 100% month-on-month in 2023. With that, we are hopeful that with our small gesture, we can create a path for others to follow.”
About Alipay+
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing solutions offered by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231214144228/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom